TWI854995B - 雜環化合物 - Google Patents

雜環化合物 Download PDF

Info

Publication number
TWI854995B
TWI854995B TW108132216A TW108132216A TWI854995B TW I854995 B TWI854995 B TW I854995B TW 108132216 A TW108132216 A TW 108132216A TW 108132216 A TW108132216 A TW 108132216A TW I854995 B TWI854995 B TW I854995B
Authority
TW
Taiwan
Prior art keywords
mhz
nmr1
compound
halogen
ring
Prior art date
Application number
TW108132216A
Other languages
English (en)
Chinese (zh)
Other versions
TW202035423A (zh
Inventor
大達一弘
藤森悠介
牧田直也
古関教孝
林秀樹
坂元裕樹
峰野胡桃
多賀亮介
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202035423A publication Critical patent/TW202035423A/zh
Application granted granted Critical
Publication of TWI854995B publication Critical patent/TWI854995B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW108132216A 2018-09-07 2019-09-06 雜環化合物 TWI854995B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018167488 2018-09-07
JP2018-167488 2018-09-07

Publications (2)

Publication Number Publication Date
TW202035423A TW202035423A (zh) 2020-10-01
TWI854995B true TWI854995B (zh) 2024-09-11

Family

ID=68063002

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108132216A TWI854995B (zh) 2018-09-07 2019-09-06 雜環化合物

Country Status (12)

Country Link
US (2) US11932657B2 (enExample)
EP (1) EP3847176A1 (enExample)
JP (1) JP7448527B2 (enExample)
KR (1) KR102810086B1 (enExample)
CN (1) CN112654627A (enExample)
AU (2) AU2019335968B2 (enExample)
CA (1) CA3109610A1 (enExample)
EA (1) EA202190654A1 (enExample)
IL (1) IL280821B2 (enExample)
SG (1) SG11202101963XA (enExample)
TW (1) TWI854995B (enExample)
WO (1) WO2020050409A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
CA3155466A1 (en) 2019-12-09 2021-06-17 Otsuka Pharmaceutical Co., Ltd. Acrylamide compounds
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ahrシグナル伝達の調節に有用なピリドピリミジン誘導体
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN115215720B (zh) * 2021-04-19 2023-08-22 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
WO2022228399A1 (zh) * 2021-04-27 2022-11-03 山东轩竹医药科技有限公司 三并环类usp1抑制剂及其用途
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN118076613A (zh) * 2021-09-02 2024-05-24 捷豹治疗有限公司 可用于调节AhR信号传导的化合物
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物
WO2024090138A1 (ja) * 2022-10-29 2024-05-02 松本油脂製薬株式会社 弾性繊維用処理剤及びその利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EA026134B1 (ru) 2010-12-16 2017-03-31 Ф. Хоффманн-Ля Рош Аг Трициклические ингибиторы pi3k и способы их применения
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
WO2016204256A1 (ja) 2015-06-16 2016-12-22 国立大学法人京都大学 高機能性血小板の製造方法
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
WO2019167973A1 (en) 2018-03-01 2019-09-06 Kyoto University Cell cycle progression inhibitor
JP7448527B2 (ja) 2018-09-07 2024-03-12 大塚製薬株式会社 ヘテロ環式化合物
CA3155466A1 (en) 2019-12-09 2021-06-17 Otsuka Pharmaceutical Co., Ltd. Acrylamide compounds
JP2022188761A (ja) 2021-06-09 2022-12-21 大塚製薬株式会社 窒素原子含有複素環化合物を用いる血小板産生方法

Also Published As

Publication number Publication date
KR20210056373A (ko) 2021-05-18
KR102810086B1 (ko) 2025-05-21
EA202190654A1 (ru) 2021-05-27
WO2020050409A1 (en) 2020-03-12
AU2024203760A1 (en) 2024-06-20
CN112654627A (zh) 2021-04-13
AU2019335968A1 (en) 2021-05-06
CA3109610A1 (en) 2020-03-12
TW202035423A (zh) 2020-10-01
JP2021536482A (ja) 2021-12-27
SG11202101963XA (en) 2021-03-30
IL280821A (en) 2021-04-29
NZ774547A (en) 2025-10-31
US20240208999A1 (en) 2024-06-27
JP7448527B2 (ja) 2024-03-12
EP3847176A1 (en) 2021-07-14
IL280821B1 (en) 2024-10-01
US20210340157A1 (en) 2021-11-04
US11932657B2 (en) 2024-03-19
IL280821B2 (en) 2025-02-01
AU2019335968B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
US11932657B2 (en) Heterocyclic compound
RU2538200C2 (ru) ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ИХ СОДЕРЖАЩАЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С КИНАЗОЙ mTOR ИЛИ КИНАЗОЙ PI3K
JP6445574B2 (ja) ブロモドメイン阻害剤
AU2024278273A1 (en) Compounds
JP6466433B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
US20120329784A1 (en) Compounds and methods
WO2009085256A1 (en) Anti-hiv compounds
JP2011507848A (ja) Rhoキナーゼインヒビターとしてのベンゾピランおよびアナログ
WO2010102154A2 (en) Biaryl oxyacetic acid compounds
CN112469714B (zh) 作为端锚聚合酶抑制剂的1,2,4-三唑衍生物
EA046483B1 (ru) Гетероциклическое соединение
CA3155466A1 (en) Acrylamide compounds
TW202229277A (zh) 用於治療隱孢子蟲病之化合物及組成物
HK40048052A (zh) 杂环化合物
RU2838187C2 (ru) Соединения
CN101171015A (zh) 作为离子通道配体的酰胺衍生物、药物组合物及其使用方法
NZ755709A (en) Aryl hydrocarbon receptor (ahr) modulator compounds